Xenon reports phase 3 epilepsy drug trial results at neurology meeting

April 19, 2026 6:00 PM

Xenon Pharmaceuticals Inc. (NASDAQ: XENE) presented data from its Phase 3 X-TOLE2 study of azetukalner for focal onset seizures at ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found